Department of Psychiatry, Wright State University School of Medicine, Dayton, OH, 45435, United States; Summit Behavioral Healthcare, Cincinnati, OH, 45237, United States.
Department of Psychiatry, Wright State University School of Medicine, Dayton, OH, 45435, United States; Summit Behavioral Healthcare, Cincinnati, OH, 45237, United States.
J Steroid Biochem Mol Biol. 2019 May;189:228-239. doi: 10.1016/j.jsbmb.2018.12.010. Epub 2019 Jan 4.
Vitamin D3 is a secosteroid hormone produced in the skin in amounts estimated up to 25,000 international units (IUs) a day by the action of UVB radiation on 7-dehydrocholesterol. Vitamin D deficiency is common due to both lack of adequate sun exposure to the skin, and because vitamin D is present in very few food sources. Deficiency is strongly linked to increased risk for a multitude of diseases, several of which have historically been shown to improve dramatically with either adequate UVB exposure to the skin, or to oral or topical supplementation with vitamin D. These diseases include asthma, psoriasis, rheumatoid arthritis, rickets and tuberculosis. All patients in our hospital have been routinely screened on admission for vitamin D deficiency since July 2011, and offered supplementation to either correct or prevent deficiency. During this time, we have admitted over 4700 patients, the vast majority of whom agreed to supplementation with either 5000 or 10,000 IUs/day. Due to disease concerns, a few agreed to larger amounts, ranging from 20,000 to 50,000 IUs/day. There have been no cases of vitamin D3 induced hypercalcemia or any adverse events attributable to vitamin D3 supplementation in any patient. Three patients with psoriasis showed marked clinical improvement in their skin using 20,000 to 50,000 IUs/day. Analysis of 777 recently tested patients (new and long-term) not on D3 revealed 28.7% with 25-hydroxyvitaminD3 (25OHD3) blood levels < 20 ng/ml, 64.1% < 30 ng/ml, a mean 25OHD3 level of 27.1 ng/ml, with a range from 4.9 to 74.8 ng/ml. Analysis of 418 inpatients on D3 long enough to develop 25OHD3 blood levels > 74.4 ng/ml showed a mean 25OHD3 level of 118.9 ng/ml, with a range from 74.4 to 384.8 ng/ml. The average serum calcium level in these 2 groups was 9.5 (no D3) vs 9.6 (D3), with ranges of 8.4 to 10.7 (no D3) vs 8.6 to 10.7 mg/dl (D3), after excluding patients with other causes of hypercalcemia. The average intact parathyroid hormone levels were 24.2 pg/ml (D3) vs. 30.2 pg/ml (no D3). In summary, long-term supplementation with vitamin D3 in doses ranging from 5000 to 50,000 IUs/day appears to be safe.
维生素 D3 是一种类固醇激素,在皮肤中产生,每天通过 UVB 辐射对 7-脱氢胆固醇的作用估计可达 25000 国际单位 (IU)。由于缺乏足够的阳光照射皮肤,以及维生素 D 存在于极少数食物来源中,维生素 D 缺乏很常见。缺乏与多种疾病的风险增加密切相关,其中一些疾病以前已经表明,通过皮肤接受足够的 UVB 照射,或通过口服或局部补充维生素 D,可以显著改善。这些疾病包括哮喘、银屑病、类风湿关节炎、佝偻病和结核病。自 2011 年 7 月以来,我们医院的所有患者在入院时都常规筛查维生素 D 缺乏症,并提供补充剂以纠正或预防缺乏症。在此期间,我们收治了超过 4700 名患者,其中绝大多数人同意每天补充 5000 或 10000 IU 的维生素 D。由于疾病的原因,少数人同意每天摄入更大剂量,范围从 20000 到 50000 IU。在任何患者中,都没有出现维生素 D3 引起的高钙血症或任何与维生素 D3 补充相关的不良反应。三名银屑病患者每天使用 20000 至 50000 IU 的维生素 D3,皮肤明显改善。对最近接受检测的 777 名(新患者和长期患者)未接受 D3 治疗的患者进行分析,发现 28.7%的患者 25-羟维生素 D3(25OHD3)血液水平<20ng/ml,64.1%<30ng/ml,平均 25OHD3 水平为 27.1ng/ml,范围为 4.9 至 74.8ng/ml。对长期接受 D3 治疗的 418 名住院患者进行分析,以达到 25OHD3 血液水平>74.4ng/ml,平均 25OHD3 水平为 118.9ng/ml,范围为 74.4 至 384.8ng/ml。这两组患者的平均血清钙水平分别为 9.5(无 D3)和 9.6(D3),范围分别为 8.4 至 10.7(无 D3)和 8.6 至 10.7mg/dl(D3),排除其他高钙血症原因的患者。平均完整甲状旁腺激素水平分别为 24.2pg/ml(D3)和 30.2pg/ml(无 D3)。综上所述,长期每天补充维生素 D3 剂量为 5000 至 50000 IU,似乎是安全的。